The Antiviral Nanotechnology Gap in COVID-19: Systematic Barriers to Pandemic-Scale Translation and Deployment

For over two decades, antiviral nanotechnologies have demonstrated robust preclinical efficacy against diverse viral pathogens, including coronaviruses. Yet during the COVID-19 pandemic, these platforms contributed minimally to the global therapeutic response despite unprecedented urgency, regulatory flexibility, and funding availability. This narrative review, structured using the DELIVER framework (Joyce et al., 2024), systematically analyses the translational barriers that constrained deployment across scientific, regulatory, manufacturing, economic, and institutional domains.
A comprehensive literature search was conducted across PubMed, Scopus, Web of Science, and Google Scholar (January 2000-December 2024), supplemented by ClinicalTrials.gov and regulatory policy documents. Following deduplication and eligibility screening of 2,847 records, 90 peer-reviewed articles were included in the qualitative synthesis (inter-rater agreement: Cohen's kappa = 0.88). Only three systemic antiviral nanotechnology trials were identified during COVID-19, none of which achieved regulatory authorisation. In contrast, mRNA-lipid nanoparticle (LNP) vaccines succeeded because of long-term pre-pandemic platform maturation, established manufacturing partnerships, early regulatory engagement, and coordinated government support through Operation Warp Speed (~$18 billion).
Key barriers included manufacturing complexity, regulatory pathway ambiguity, absent pandemic-ready production capacity, fragmented intellectual property landscapes, and weak cross-sector coordination. Crucially, these barriers did not operate independently but formed mutually reinforcing cascades that rendered single-domain interventions insufficient. Partial successes--including diagnostic nanoparticle platforms and liposomal oncology reformulations--demonstrate that context-specific enabling factors, rather than inherent technological limitations, largely determined translation outcomes. Advancing antiviral nanotechnologies for future pandemics requires proactive, inter-pandemic investment in scalable manufacturing, clearer regulatory frameworks, platform-based development strategies, and coordinated economic instruments. This principally US-focused analysis offers policy insights applicable across high-income country (HIC) and, selectively, lower-middle-income country (LMIC) settings.

antiviral nanotechnology; pandemic preparedness; translational barriers

1. Abdelmonem, R., Ayman, M., Lofty, S. E., Ezzat, Y., Nabeah, J. M., Mohamed, H., & Eltahan, M. (2025). Advancing nanoparticle production: Scaling up techniques, challenges, and future perspectives in pharmaceutical applications. Journal of Pharmaceutical Sciences and Drug Manufacturing, 2(2), 26-39. [Google Scholar] [Crossref]

2. Afonin, K. A., Dobrovolskaia, M. A., Church, G., & Bathe, M. (2021). Opportunities, barriers, and a strategy for overcoming translational challenges to therapeutic nucleic acid nanotechnology. Therapeutic RNA Nanotechnology, 605-623. [Google Scholar] [Crossref]

3. Afonin, K. A., Dobrovolskaia, M. A., Ke, W., Grodzinski, P., & Bathe, M. (2022). Critical review of nucleic acid nanotechnology to identify gaps and inform a strategy for accelerated clinical translation. Advanced Drug Delivery Reviews, 181, 114081. [Google Scholar] [Crossref]

4. Anjum, S., Ishaque, S., Fatima, H., Farooq, W., Hano, C., Abbasi, B. H., & Anjum, I. (2021). Emerging applications of nanotechnology in healthcare systems: Grand challenges and perspectives. Pharmaceuticals, 14(8), 707. [Google Scholar] [Crossref]

5. Banala, V. T., Mukherjee, D., Mahajan, S., & Singh, P. K. (2022). Current status of FDA-approved marketed nano drug products: Regulatory considerations. In Multifunctional Nanocarriers (pp. 501-521). Elsevier. [Google Scholar] [Crossref]

6. Begines, B., Ortiz, T., Perez-Aranda, M., Martinez, G., Merinero, M., Arguelles-Arias, F., & Alcudia, A. (2020). Polymeric nanoparticles for drug delivery: Recent developments and future prospects. Nanomaterials, 10(7), 1403. [Google Scholar] [Crossref]

7. Caputo, F., Mehn, D., Clogston, J. D., Rosslein, M., Prina-Mello, A., Borgos, S. E., & Calzolai, L. (2021). Asymmetric-flow field-flow fractionation for measuring particle size, drug loading and (in)stability of nanopharmaceuticals. Journal of Chromatography A, 1635, 461767. [Google Scholar] [Crossref]

8. Chakraborty, C., Sharma, A. R., Bhattacharya, M., Agoramoorthy, G., & Lee, S.-S. (2021). The drug repurposing for COVID-19 clinical trials provide very effective therapeutic combinations. Frontiers in Pharmacology, 12, 704205. [Google Scholar] [Crossref]

9. Chakravarty, M., & Vora, A. (2021). Nanotechnology-based antiviral therapeutics. Drug Delivery and Translational Research, 11(3), 748-787. [Google Scholar] [Crossref]

10. Chen, S., Huang, X., Xue, Y., et al. (2023). Nanotechnology-based mRNA vaccines. Nature Reviews Methods Primers, 3, 63. [Google Scholar] [Crossref]

11. Congressional Research Service (CRS). (2021). Operation Warp Speed contracts for COVID-19 vaccines and ancillary vaccination materials. [Google Scholar] [Crossref]

12. Croci, R., Bottaro, E., Chan, K. W. K., Watanabe, S., Pezzullo, M., Mastrangelo, E., & Nastruzzi, C. (2016). Liposomal systems as nanocarriers for the antiviral agent ivermectin. International Journal of Biomaterials, 2016, 8043983. [Google Scholar] [Crossref]

13. Csoka, I., Ismail, R., Jojart-Laczkovich, O., & Pallagi, E. (2021). Regulatory considerations, challenges and risk-based approach in nanomedicine development. Current Medicinal Chemistry, 28(36), 7461-7476. [Google Scholar] [Crossref]

14. de Souza Cardoso Delfino, C., de Paula Pereira, M. C., dos Santos Oliveira, M., et al. (2025). Scaling nanopharmaceutical production for personalized medicine: Challenges and strategies. Journal of Nanoparticle Research, 27, 108. [Google Scholar] [Crossref]

15. Diversa Technologies. (2025). Overcoming regulatory hurdles in clinical translation of nanomedicine. https://www.diversatechnologies.com [Google Scholar] [Crossref]

16. Dri, D. A., Rinaldi, F., Carafa, M., et al. (2023). Nanomedicines and nanocarriers in clinical trials: Surfing through regulatory requirements and physico-chemical critical quality attributes. Drug Delivery and Translational Research, 13, 757-769. [Google Scholar] [Crossref]

17. Dung, T. T. N., Nam, V. N., Nhan, T. T., Ngoc, T. T. B., Minh, L. Q., Nga, B. T. T., & Quang, D. V. (2020). Silver nanoparticles as potential antiviral agents against African swine fever virus. Materials Research Express, 6(12), 1250g9. [Google Scholar] [Crossref]

18. Eastman, R. T., Roth, J. S., Brimacombe, K. R., Simeonov, A., Shen, M., Patnaik, S., & Hall, M. D. (2020). Remdesivir: A review of its discovery and development leading to emergency use authorization for treatment of COVID-19. ACS Central Science, 6(5), 672-683. [Google Scholar] [Crossref]

19. Falanga, A., Del Genio, V., & Galdiero, S. (2021). Peptides and dendrimers: How to combat viral and bacterial infections. Pharmaceutics, 13(1), 101. [Google Scholar] [Crossref]

20. FDA. (2017). Drug products, including biological products, that contain nanomaterials: Guidance for industry (Draft). [Google Scholar] [Crossref]

21. FDA. (2018). Nanotechnology guidance documents. https://www.fda.gov/science-research/nanotechnology-programs-fda/nanotechnology-guidance-documents [Google Scholar] [Crossref]

22. FDA. (2022). Drug products, including biological products, that contain nanomaterials: Guidance for industry. [Google Scholar] [Crossref]

23. Ferdous, Z., & Nemmar, A. (2020). Health impact of silver nanoparticles: A review of the biodistribution and toxicity following various routes of exposure. International Journal of Molecular Sciences, 21(7), 2375. [Google Scholar] [Crossref]

24. Fernandes, C., Jathar, M., Sawant, B. K. S., & Warde, T. (2023). Scale-up of nanoparticle manufacturing process. In A. B. Jindal (Ed.), Pharmaceutical Process Engineering and Scale-up Principles. Springer. [Google Scholar] [Crossref]

25. Filipczak, N., Yalamarty, S. S. K., Li, X., Parveen, F., & Torchilin, V. (2021). Developments in treatment methodologies using dendrimers for infectious diseases. Molecules, 26(11), 3304. [Google Scholar] [Crossref]

26. Foulkes, R., Man, E., Thind, J., Yeung, S., Joy, A., & Hoskins, C. (2020). The regulation of nanomaterials and nanomedicines for clinical application: Current and future perspectives. Biomaterials Science, 8(17), 4653-4664. [Google Scholar] [Crossref]

27. Ghosh, D., & Kumar, A. (2024). Regulatory landscape and expedited pathways for nanomedicines. Drug Discovery Today, 29(3), 103-115. [Google Scholar] [Crossref]

28. Giubilato, E., Cazzagon, V., Amorim, M. J. B., Blosi, M., Bouillard, J., Bouwmeester, H., & Hristozov, D. (2020). Risk management framework for nano-biomaterials used in medical devices and advanced therapy medicinal products. Materials, 13(20), 4532. [Google Scholar] [Crossref]

29. Gote, V., Bolla, P. K., Kommineni, N., Butreddy, A., Nukala, P. K., Palakurthi, S. S., & Khan, W. (2023). A comprehensive review of mRNA vaccines. International Journal of Molecular Sciences, 24(3), 2700. [Google Scholar] [Crossref]

30. Guerrini, G., Magri, D., Gioria, S., et al. (2022). Characterization of nanoparticles-based vaccines for COVID-19. Nature Nanotechnology, 17, 570-576. [Google Scholar] [Crossref]

31. Guy, R. K., DiPaola, R. S., Romanelli, F., & Dutch, R. E. (2020). Rapid repurposing of drugs for COVID-19. Science, 368(6493), 829-830. [Google Scholar] [Crossref]

32. Hashiba, K., Taguchi, M., Sakamoto, S., et al. (2024). Overcoming thermostability challenges in mRNA-lipid nanoparticle systems with piperidine-based ionizable lipids. Communications Biology, 7, 556. [Google Scholar] [Crossref]

33. Hu, C., He, X., Gao, H., & Zhang, J. (2025). DELIVER: The core principles for the clinic translation of nanomedicines. Acta Pharmaceutica Sinica B, 15(2), 1196-1198. [Google Scholar] [Crossref]

34. Javan, F., Vatanara, A., Azadmanesh, K., Nabi-Meibodi, M., & Shakouri, M. (2017). Encapsulation of ritonavir in solid lipid nanoparticles: In-vitro anti-HIV-1 activity using lentiviral particles. The Journal of Pharmacy and Pharmacology, 69(8), 1002-1009. [Google Scholar] [Crossref]

35. Jbara-Agbaria, D., Blondzik, S., Burger-Kentischer, A., Agbaria, M., Nordling-David, M. M., Giterman, A., & Golomb, G. (2022). Liposomal siRNA formulations for the treatment of herpes simplex virus-1. Pharmaceutics, 14(3), 633. [Google Scholar] [Crossref]

36. Joudeh, N., & Linke, D. (2022). Nanoparticle classification, physicochemical properties, characterization, and applications: A comprehensive review for biologists. Journal of Nanobiotechnology, 20, 262. [Google Scholar] [Crossref]

37. Joyce, P., Allen, C. J., Alonso, M. J., Ashford, M., Bradbury, M. S., Germain, M., & Santos, H. A. (2024). A translational framework to DELIVER nanomedicines to the clinic. Nature Nanotechnology, 19(11), 1597-1611. [Google Scholar] [Crossref]

38. Kashte, S., Gulbake, A., El-Amin, S. F., III, et al. (2021). COVID-19 vaccines: Rapid development, implications, challenges and future prospects. Human Cell, 34, 711-733. [Google Scholar] [Crossref]

39. Khairnar, S. V., Pagare, P., Thakre, A., Nambiar, A. R., Junnuthula, V., Abraham, M. C., & Dyawanapelly, S. (2022). Review on the scale-up methods for the preparation of solid lipid nanoparticles. Pharmaceutics, 14(9), 1886. [Google Scholar] [Crossref]

40. Kim, E., Lim, E. K., Park, G., Park, C., Lim, J. W., Lee, H., & Haam, S. (2021). Advanced nanomaterials for preparedness against (re-)emerging viral diseases. Advanced Materials, 33(47), 2005927. [Google Scholar] [Crossref]

41. Kirtane, A. R., Verma, M., Karandikar, P., et al. (2021). Nanotechnology approaches for global infectious diseases. Nature Nanotechnology, 16, 369-384. [Google Scholar] [Crossref]

42. Kwon, S., Youtie, J., Porter, A., et al. (2024). How does regulatory uncertainty shape the innovation process? Evidence from the case of nanomedicine. Journal of Technology Transfer, 49, 262-302. [Google Scholar] [Crossref]

43. Lamb, Y. N. (2020). Remdesivir: First approval. Drugs, 80, 1355-1363. [Google Scholar] [Crossref]

44. Lamoot, A., Lammens, J., De Lombaerde, E., Zhong, Z., Gontsarik, M., Chen, Y., & De Geest, B. G. (2023). Successful batch and continuous lyophilization of mRNA LNP formulations depend on cryoprotectants and ionizable lipids. Biomaterials Science, 11(12), 4327-4334. [Google Scholar] [Crossref]

45. Liu, X., & Meng, H. (2021). Consideration for the scale-up manufacture of nanotherapeutics: A critical step for technology transfer. VIEW, 2(5), 20200190. [Google Scholar] [Crossref]

46. Lloyd, E. C., Gandhi, T. N., & Petty, L. A. (2021). Monoclonal antibodies for COVID-19. JAMA, 325(10), 1015. [Google Scholar] [Crossref]

47. Malik, R., & Patil, S. (2020). Nanotechnology: Regulatory outlook on nanomaterials and nanomedicines in United States, Europe and India. Applied Clinical Research, Clinical Trials and Regulatory Affairs, 7(3), 225-236. [Google Scholar] [Crossref]

48. Mangla, B., Kumar, P., Javed, S., Pathan, T., Ahsan, W., & Aggarwal, G. (2025). Regulating nanomedicines: Challenges, opportunities, and the path forward. Nanomedicine, 20(15), 1911-1927. [Google Scholar] [Crossref]

49. Marovich, M., Mascola, J. R., & Cohen, M. S. (2020). Monoclonal antibodies for prevention and treatment of COVID-19. JAMA, 324(2), 131-132. [Google Scholar] [Crossref]

50. Mastrangelo, E., Mazzitelli, S., Fabbri, J., Rohayem, J., Ruokolainen, J., Nykanen, A., & Bolognesi, M. (2014). Delivery of suramin as an antiviral agent through liposomal systems. ChemMedChem, 9(5), 933-939. [Google Scholar] [Crossref]

51. Metselaar, J. M., & Lammers, T. (2020). Challenges in nanomedicine clinical translation. Drug Delivery and Translational Research, 10, 721-725. [Google Scholar] [Crossref]

52. Ndayishimiye, J., Kumeria, T., Popat, A., Falconer, J. R., & Blaskovich, M. A. (2022). Nanomaterials: The new antimicrobial magic bullet. ACS Infectious Diseases, 8(4), 693-712. [Google Scholar] [Crossref]

53. Okafor, N. I., & Nnaji, N. J. (2024). Liposomes, facilitating the encapsulation and improved solubility of zidovudine antiretroviral drug. BioNanoScience, 14, 4877-4894. [Google Scholar] [Crossref]

54. Pallerla, S., Pires, I. S., Melo, M. B., Yun, D., Wagner, A., Budai, M., & Irvine, D. J. (2025). Scale-up and cGMP manufacturing of next-generation vaccine adjuvant saponin/MPLA nanoparticles (SMNP). Journal of Pharmaceutical Sciences, 103913. [Google Scholar] [Crossref]

55. Patel, J. K., & Pathak, Y. V. (Eds.). (2021). Emerging technologies for nanoparticle manufacturing (pp. 109-128). Springer. [Google Scholar] [Crossref]

56. Peter, R. M. (2025). mRNA vaccine funding cuts: The impact on U.S. healthcare and biotech. Labiotech. [Google Scholar] [Crossref]

57. Pokrajac, L., Abbas, A., Chrzanowski, W., Dias, G. M., Eggleton, B. J., Maguire, S., & Mitra, S. (2021). Nanotechnology for a sustainable future. ACS Nano, 15(11), 18608-18623. [Google Scholar] [Crossref]

58. Pu, Y., Zhu, C., Liao, J., Gong, L., Wu, Y., Liu, S., Wang, H., Zhang, Q., & Lin, Z. (2025). Antiviral nanomedicine: Advantages, mechanisms and advanced therapies. Bioactive Materials, 52, 92-122. [Google Scholar] [Crossref]

59. Rai, M., Bonde, S., Yadav, A., Plekhanova, Y., Reshetilov, A., Gupta, I., & Ingle, A. P. (2022). Nanotechnology-based promising strategies for the management of COVID-19. Expert Review of Anti-Infective Therapy, 20(10), 1299-1308. [Google Scholar] [Crossref]

60. Ratan, Z. A., Mashrur, F. R., Chhoan, A. P., Shahriar, S. M., Haidere, M. F., Runa, N. J., & Cho, J. Y. (2021). Silver nanoparticles as potential antiviral agents. Pharmaceutics, 13(12), 2034. [Google Scholar] [Crossref]

61. Reinhart, A. G., Osterwald, A., Ringler, P., Leiser, Y., Lauer, M. E., Martin, R. E., & Keller, M. (2023). Investigations into mRNA lipid nanoparticles shelf-life stability under nonfrozen conditions. Molecular Pharmaceutics, 20(12), 6492-6503. [Google Scholar] [Crossref]

62. Riva, L., Yuan, S., Yin, X., Martin-Sancho, L., Matsunaga, N., Pache, L., & Chanda, S. K. (2020). Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing. Nature, 586(7827), 113-119. [Google Scholar] [Crossref]

63. Rupp, R., Rosenthal, S. L., & Stanberry, L. R. (2007). VivaGel (SPL7013 Gel): A candidate dendrimer-microbicide for the prevention of HIV and HSV infection. International Journal of Nanomedicine, 2(4), 561-566. [Google Scholar] [Crossref]

64. Shah, S., Nene, S., Rangaraj, N., Raghuvanshi, R. S., Singh, S. B., & Srivastava, S. (2020). Bridging the gap: Academia, industry and FDA convergence for nanomaterials. Drug Development and Industrial Pharmacy, 46(11), 1735-1746. [Google Scholar] [Crossref]

65. Shan, X., Gong, X., Li, J., Wen, J., Li, Y., & Zhang, Z. (2022). Current approaches of nanomedicines in the market and various stage of clinical translation. Acta Pharmaceutica Sinica B, 12(7), 3028-3048. [Google Scholar] [Crossref]

66. Sharifi, S., Mahmoud, N. N., Voke, E., et al. (2022). Importance of standardizing analytical characterization methodology for improved reliability of the nanomedicine literature. Nano-Micro Letters, 14, 172. [Google Scholar] [Crossref]

67. Shegokar, R., & Nakach, M. (2020). Large-scale manufacturing of nanoparticles: An industrial outlook. In Drug Delivery Aspects (pp. 57-77). Elsevier. [Google Scholar] [Crossref]

68. Sher, E. K., Alebic, M., Boras, M. M., Boskailo, E., Farhat, E. K., Karahmet, A., & Lekic, L. (2024). Nanotechnology in medicine revolutionizing drug delivery for cancer and viral infection treatments. International Journal of Pharmaceutics, 660, 124345. [Google Scholar] [Crossref]

69. Sindhwani, S., & Chan, W. C. (2021). Nanotechnology for modern medicine: Next step towards clinical translation. Journal of Internal Medicine, 290(3), 486-498. [Google Scholar] [Crossref]

70. Singh, Y. D., Ningthoujam, R., Panda, M. K., Jena, B., Babu, P. J., & Mishra, A. K. (2021). Insight from nanomaterials and nanotechnology towards COVID-19. Sensors International, 2, 100099. [Google Scholar] [Crossref]

71. Souri, M., Chiani, M., Farhangi, A., Mehrabi, M. R., Nourouzian, D., Raahemifar, K., & Soltani, M. (2022). Anti-COVID-19 nanomaterials: Directions to improve prevention, diagnosis, and treatment. Nanomaterials, 12(5), 783. [Google Scholar] [Crossref]

72. Souto, E. B., Silva, G. F., Dias-Ferreira, J., Zielinska, A., Ventura, F., Durazzo, A., & Santini, A. (2020). Nanopharmaceutics: Part I - Clinical trials legislation and GMP of nanotherapeutics in the EU. Pharmaceutics, 12(2), 146. [Google Scholar] [Crossref]

73. Stanberry, L. R. (2007). VivaGel (SPL7013 Gel): A candidate dendrimer-microbicide for the prevention of HIV and HSV infection. International Journal of Nanomedicine, 2(4), 561-566. [Google Scholar] [Crossref]

74. Stretz, H. A., Kiss, A., Mealio, K. N., & Ayeni, O. O. (2025). Regulatory and environmental issues of nanotechnology safety. In Nanotechnology Safety (pp. 59-76). Elsevier. [Google Scholar] [Crossref]

75. Tang, Z., Zhang, X., Shu, Y., Guo, M., Zhang, H., & Tao, W. (2021). Insights from nanotechnology in COVID-19 treatment. Nano Today, 36, 101019. [Google Scholar] [Crossref]

76. Thapa, R. K., & Kim, J. O. (2023). Nanomedicine-based commercial formulations: Current developments and future prospects. Journal of Pharmaceutical Investigation, 53, 19-33. [Google Scholar] [Crossref]

77. Thi, T. T. H., Suys, E. J. A., Lee, J. S., Nguyen, D. H., Park, K. D., & Truong, N. P. (2021). Lipid-based nanoparticles in the clinic and clinical trials: From cancer nanomedicine to COVID-19 vaccines. Vaccines, 9(4), 359. [Google Scholar] [Crossref]

78. Traversing the valley of death. (2023). Nature Reviews Bioengineering, 1, 875. [Google Scholar] [Crossref]

79. Tureli, N. G., & Tureli, A. E. (2020). Upscaling and GMP production of pharmaceutical drug delivery systems. In Drug Delivery Trends (pp. 215-229). Elsevier. [Google Scholar] [Crossref]

80. U.S. National Library of Medicine. (n.d.). ClinicalTrials.gov. https://clinicaltrials.gov/ [Google Scholar] [Crossref]

81. Vahedifard, F., & Chakravarthy, K. (2021). Nanomedicine for COVID-19: The role of nanotechnology in the treatment and diagnosis of COVID-19. Emergent Materials, 4, 75-99. [Google Scholar] [Crossref]

82. Van Norman, G. A. (2020). "Warp Speed" operations in the COVID-19 pandemic: Moving too quickly? JACC: Basic to Translational Science, 5(7), 730-734. [Google Scholar] [Crossref]

83. Varahachalam, S. P., Lahooti, B., Chamaneh, M., Bagchi, S., Chhibber, T., Morris, K., & Kaushik, A. (2021). Nanomedicine for the SARS-CoV-2: State-of-the-art and future prospects. International Journal of Nanomedicine, 16, 539-560. [Google Scholar] [Crossref]

84. Webb, C., Forbes, N., Roces, C. B., Anderluzzi, G., Lou, G., Abraham, S., & Perrie, Y. (2020). Using microfluidics for scalable manufacturing of nanomedicines from bench to GMP. International Journal of Pharmaceutics, 582, 119266. [Google Scholar] [Crossref]

85. Wu, L. P., Wang, D., & Li, Z. (2020). Grand challenges in nanomedicine. Materials Science and Engineering: C, 106, 110302. [Google Scholar] [Crossref]

86. Xu, C., Lei, C., Hosseinpour, S., Ivanovski, S., Walsh, L. J., & Khademhosseini, A. (2022). Nanotechnology for the management of COVID-19 during the pandemic and in the post-pandemic era. National Science Review, 9(10), nwac124. [Google Scholar] [Crossref]

87. Yang, D. (2021). Application of nanotechnology in the COVID-19 pandemic. International Journal of Nanomedicine, 16, 623-649. [Google Scholar] [Crossref]

88. Yang, K. C., Lin, J. C., Tsai, H. H., Hsu, C. Y., Shih, V., & Hu, C. J. (2021). Nanotechnology advances in pathogen- and host-targeted antiviral delivery: Multipronged therapeutic intervention for pandemic control. Drug Delivery and Translational Research, 11(4), 1420-1437. [Google Scholar] [Crossref]

89. Younis, M. A., Tawfeek, H. M., Abdellatif, A. A., Abdel-Aleem, J. A., & Harashima, H. (2022). Clinical translation of nanomedicines: Challenges, opportunities, and keys. Advanced Drug Delivery Reviews, 181, 114083. [Google Scholar] [Crossref]

90. Zhang, C., Yan, L., Wang, X., Zhu, S., Chen, C., Gu, Z., & Zhao, Y. (2020). Progress, challenges, and future of nanomedicine. Nano Today, 35, 101008. [Google Scholar] [Crossref]

91. Zheng, C., Li, M., & Ding, J. (2021). Challenges and opportunities of nanomedicines in clinical translation. Bio Integration, 2(2), 57. [Google Scholar] [Crossref]

• Measuring Waste of Patient Time in Health Care at Non-Digitized Hospital: An Observational Study in Bangabandhu Sheikh Mujib Medical University, Bangladesh
• Reaffirming Clinical Confidence in Atorvastatin Therapy: A Digital Outreach Case Study from Tamil Nadu, India
• Clinical Manifestations and Therapeutic Response in a Patient with Hypothyroidism: A Case Report
• Eranda (Ricinus Communis) In Gridhrasi (Sciatica): Classical Rationale, Pharmacology and Clinical Evidence- A Narrative Literature Review
• Magnetotherapy in Pain Management: Mechanisms, Clinical Applications, and Future Perspectives – A Review